PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ChemImage Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

James S. McGlone Joins ChemImage Corporation as President - ChemImage, a leader in Chemical Imaging technology, is pleased to announce the addition of James S. McGlone to the executive management team. James S. McGlone joined ChemImage effective June 1st, 2008
James S. McGlone Joins ChemImage Corporation as President

 

NewswireToday - /newswire/ - Pittsburgh, PA, United States, 2008/06/17 - ChemImage, a leader in Chemical Imaging technology, is pleased to announce the addition of James S. McGlone to the executive management team. James S. McGlone joined ChemImage effective June 1st, 2008.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“I am very excited about the opportunity at ChemImage.”James S. McGlone stated. “I look forward to exploiting ChemImage’s strong patent portfolio and leveraging our unique Molecular and Chemical Imaging abilities. With our unique abilities we will differentiate ourselves from other suppliers of imaging technologies.”

McGlone is the most recent addition to the ChemImage management team that has been transitioning over the last seven months. “We are extremely pleased that Mr. McGlone has joined the ChemImage family,” stated John Belechak, ChemImage Chief Operating Officer. “Jim’s an experienced business professional with firmly established leadership skills. He affords ChemImage the ability to think strategically at a higher level and provides invaluable business expertise,” Belechak added.

McGlone joins ChemImage after several years as the President of Galil Medical where he drove the expansion of Galil’s cryotherapy business. McGlone was also the President of Oncura which was a joint venture between General Electric (NYSE:GE) and Galil Medical, Ltd. Prior to joining Galil Medical, McGlone spent fourteen years in various sales and management roles with Siemens Medical Systems Inc., a subsidiary of Siemens AG (NYSE:SI).

McGlone holds an MBA from Stern Business School at New York University, a MS in Bioengineering from the Pennsylvania State University and a BA in Engineering and Applied Science from Yale University.

About ChemImage
ChemImage Corporation (chemimage.com) is a world leader in Chemical Imaging technologies; provides instrumentation, software and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.

ChemImage’s main headquarters is located in Pittsburgh, Pennsylvania and houses research and development laboratories as well as engineering and manufacturing facilities.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ChemImage Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


James S. McGlone Joins ChemImage Corporation as President

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Linda Batykefer - ChemImage.com 
412-241-7335 x269 batykefer[.]chemimage.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChemImage Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ChemImage Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)